Previous 10 | Next 10 |
2023-06-08 07:39:39 ET Summary We analyzed Novartis pipeline growth versus patent expiration. Positive adjuvant data for Kisqali could accelerate market share shifts. Novartis' equal weight rating is due to high margin sales lost to generics and risks from US healthcare reform...
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA PR Newswi...
2023-06-07 15:05:00 ET Novartis (NYSE: NVS) is a company in transition. Over the past several years, the Swiss multinational pharma giant has been busy divesting key assets such as its eye care unit Alcon , trimming costs, and reducing staff in an effort to morph into a pure-pla...
2023-06-05 11:46:34 ET Summary Novartis has significantly outperformed the market since my last article and is now a Hold. Most of the outperformance is due to multiple expansion. Earnings are likely to expand from both blockbuster drug growth and the Sandoz spinoff. Novar...
2023-06-05 04:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-06-04 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead
2023-06-02 15:00:55 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-06-02 08:43:17 ET Announcing data from its pivotal study NATALEE, Novartis ( NYSE: NVS ) announced Friday that its oral breast cancer therapy Kisqali as a combination regimen lowered the risk of cancer recurrence by 25% in certain patients with early breast cancer. The glob...
2023-05-31 05:55:18 ET Summary Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The compan...
2023-05-28 09:15:00 ET With savvy stock-picking and a bit of patience, building wealth isn't as difficult as it is often made out to be. This is because quality businesses grow their revenue and profits, which makes their shares more valuable over time. Shares of AstraZeneca (NASD...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...